This section of the early value assessment interim statement describes the processes and methods that are being used for the early value assessment pilots. Different approaches are being tested to ...
Despite new methodologies and flexible regulatory pathways, CNS biopharmaceuticals still face significant safety assessment ...
Unele rezultate au fost ascunse, deoarece pot fi inaccesibile pentru dvs.
Afișați rezultatele inaccesibile